Performance of the new version (v2.0) of the GenoType MTBDRsl test for detection of resistance to second-line drugs in multidrug-resistant mycobacterium tuberculosis complex strains

Journal of Clinical Microbiology

Volumn 54, Issue 6, 2016, Pages 1573-1580

  Brossier, Florence ^a,b   Guindo, David ^a   Pham, Anne ^a   Reibel, Florence ^a,b   Sougakoff, Wladimir ^a,b   Veziris, Nicolas ^a,b   Aubry, Alexandra ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; CONTROLLED STUDY; DNA SEQUENCE; EIS GENE; GENE; GENE MUTATION; GENOTYPE; GYRA GENE; GYRB GENE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RRS GENE; SENSITIVITY AND SPECIFICITY; BACTERIAL GENE; DRUG EFFECTS; EVALUATION STUDY; GENETICS; GENOTYPING TECHNIQUE; HUMAN; MICROBIAL SENSITIVITY TEST; MUTATION; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

AMIKACIN; ANTITUBERCULAR AGENTS; CAPREOMYCIN; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GENES, BACTERIAL; GENOTYPING TECHNIQUES; HUMANS; KANAMYCIN; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84970024196     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00051-16     Document Type: Article

References (34)

1. World Health Organization. 2015. Global tuberculosis report 2015. WHO/HTM/TB/2015.22. World Health Organization, Geneva, Switzerland.
2. World Health Organization. 2008. Guidelines for the programmatic management of drug-resistant tuberculosi s: Emergency update 2008. WHO HTM/TB/2008.402. World Health Organization, Geneva, Switzerland.
3. Kliiman K, Altraja A. 2009. Predictors of poor treatment outcome in multi-and extensively drug-resistant pulmonary TB. Eur Respir J 33: 1085-1094. http://dx.doi.org/10.1183/09031936.00155708.
4. Maruri F Sterling TR Kaiga AW Blackman A van der Heijden YF Mayer C Cambau E Aubry A. 2012 A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tubercul osis and a proposed gyrase numbering system J Antimicrob Chemother 67 819-831 http://dx.doi.org/10.1093/jac/dkr566.
5. Pantel A, Petrella S, Veziris N, Brossier F, Bastian S, Jarlier V, Mayer C, Aubry A. 2012. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob Agents Chemother 56:1990-1996. http://dx.doi.org/10.1128/AAC.06272-11.
6. Maus CE, Plikaytis BB, Shinnick TM. 2005. Molecular analysis of crossresistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49:3192-3197. http://dx.doi.org/10.1128/AAC.49.8.3192-3197.2005.
7. Chakravorty S, Lee JS, Cho EJ, Roh SS, Smith LE, Lee J, Kim CT, Via LE, Cho SN, Barry CE, III, Alland D. 2015. Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low lev el drug resistance than phenotypic Lowenstein-Jensen testing. J Clin Microbiol 53:43-51. http://dx.doi.org/10.1128/JCM.02059-14.
8. Gikalo MB, Nosova EY, Krylova LY, Moroz AM. 2012. The role of eis mutations in the development of kanamycin resistance in Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother 67:2107-2109. http://dx.doi.org/10.1093/jac/dks178.
9. Zaunbrech er MA, Sikes RD, Jr, Metchock B, Shinnick TM, Posey JE. 2009. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 106:20004-20009. http://dx.doi.org/10.1073/pnas.0907925106.
10. World Health Organization. 2013. Expert group meeting report: The use of molecular line probe assay for the detection of resistance to secon d-line anti-tuberculosis drugs. WHO/HTM/TB/2013.01. World Health Organization, Geneva, Switzerland.
11. Feng Y, Liu S, Wang Q, Wang L, Tang S, Wang J, Lu W. 2013. Rapid diagnosis of dru g resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: A metaanalysis. PLoS One 8:e55292. http://dx.doi.org/10.1371/journal.pone.0055292.
12. Canetti G, Rist N, Grosset J. 1963. Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation. Rev Tuberc Pneumol (Paris) 27:2 17-272. (In French.)
13. World Health Organization. 2008. Policy guidance on drugsusceptibility testing (DST) of second-line antituberculosis drugs. WHO/HTM/TB/2008.392. World Health Organization, Geneva, Switzerland.
14. Hain Lifescience GmbH. 2015. GenoType MTBDRsl Ver2.0: Instruction manual. Hain Lifescience GmbH, Nehren, Germany.
15. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. 2010. Detec tion by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-Resistant mycobacterium tuberculosis complex isolates. J Clin Microbiol 48:1683-1689. http://dx.doi.org/10.1128/JCM.0 1947-09.
16. Dean AG, Sullivan KM, Soe MM. 2014. OpenEpi: Open source epidemiologic statistics for public health, version 3.03. www.OpenEpi.com. Updated 22 September 2014.
17. Camus JC, Pryor MJ, Medigue C, Cole ST. 2002. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 148:2967-2973. http://dx.doi.org/10.1099/00221287-148-10-296 7.
18. Brossier F, Sougakoff W, Bernard C, Petrou M, Adeyema K, Pham A, Amy de la Breteque D, Vallet M, Jarlier V, Sola C, Veziris N. 2015. Molecular analysis of the embCAB locus and e mbR gene involved in ethambutol resistance in clinical isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother 59:4800-4808. http://dx.doi.org/10.1128/AAC.00150-15.
19. Theron G, Peter J, Richardson M, Barnard M, Donegan S, Warren R, Steingart KR, Dheda K. 2014. The diagnostic accuracy of the Geno-Type(® ) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev 10:CD010705. http://dx.doi.org/10.1002/14651858.CD010705.pub2.
20. Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, MansjöM, Hoffner S, Hillemann D, Zalutskaya A, Skrahi na A, Cirillo DM. 2015. Diagnostic performance of the new version of GenoType MTBDRsl (v2.0) assay for detection of resistance to fluoroquinolones and second-line injectable drugs: A multicenter study. J Clin Microbiol 53:296 1-2969. http://dx.doi.org/10.1128/JCM.01257-15.
21. Bernard C, Veziris N, Brossier F, Sougakoff W, Jarlier V, Robert J, Aubry A. 2015. Molecular diagnosis of fluoroquinolone resistance in Mycobact erium tuberculosis. Antimicrob Agents Chemother 59:1519-1524. http://dx.doi.org/10.1128/AAC.04058-14.
22. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. 2012. New insights into fluor oquinolone resistance in Mycobacterium tuberculosis: Functional genetic analysis of gyrA and gyrB mutations. PLoS One 7:e39754. http://dx.doi.org/10.1371/journal.pone.0039754.
23. Aubry A, Sougakoff W, Bodzongo P, Delcroix G, Armand S, Millot G, Jarlier V, Courcol R, Lemaî tre N. 2014. First evaluation of drug-resistant Mycobacterium tuberculosis clinical isolates from Congo revealed misdetection of fluoroquinolone resista nce by line probe assay due to a double substitution T80A-A90G in GyrA. PLoS One 9:e95083. http://dx.doi.org/10.1371/journal.pone.0095083.
24. Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, Palomino JC, da Silva PA. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 53:4498-4500. http://dx.doi.org/10.1128/AAC.002 87-09.
25. Campbell PJ Morlock GP Sikes RD Dalton TL Metchock B Starks AM Hooks DP Cowan LS Plikaytis BB Posey JE. 2011 Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis Antimicrob Agents Chemother 55 2032-2041 http://dx.doi.org/10.1128/AAC.01550-10.
26. Engström A, Perskvist N, Werngren J, Hoffner SE, Juréen P. 2011. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 66:1247-1254. http://dx.doi.org/10.1093/jac/dkr109.
27. Hoshide M, Qian L, Rodrigues C, Warren R, Victor T, Evasco HB, II, Tupasi T, Crudu V, Douglas JT. 20 14. Geographical differences associated with single-nucleotide polymorphisms (SNPs) in nine gene targets among resistant clinical isolates of Mycobacterium tuberculosis. J Clin Microbiol 52:1322-1329. http://dx.doi.org/10.1128/J CM.00857-13.
28. Maus CE, Plikaytis BB, Shinnick TM. 2005. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49:571-577. http://dx.doi.org /10.1128/AAC.49.2.571-577.2005.
29. Reeves AZ, Campbell PJ, Sultana R, Malik S, Murray M, Plikaytis BB, Shinnick TM, Posey JE. 2013. Aminoglycoside cross-resistance in Mycobacterium tuberculosis due to mutations in the 5= untranslated region of whiB7. Antimicrob Agents Chemother 57:1857-1865. http://dx.doi.org/10.1128/AAC.02191-12.
30. Du Q, Dai G, Long Q, Yu X, Dong L, Huang H, Xie J. 2013. Mycobacterium tuberculosis rrs A1401G mutation correlates with high-level resistance to kanamycin, amikacin, and capreomycin in clinical isolates from mainland China. Diagn Microbiol Infect Dis 77:138-142. http: //dx.doi.org/10.1016/j.diagmicrobio.2013.06.031.
31. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. 2012. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: A systematic review. PLoS One 7:e33275. http://dx.doi.org/10.1371/journal.pone.0033275.
32. Fillion A, Aubry A, Brossier F, Chauffour A, Jarlier V, Veziris N. 2013. Impact of fluoroq uinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. Antimicrob Agents Chemother 57:4496-4500. http://dx.doi.org/10.1128/AAC.00506-13.
33. Po issy J, Aubry A, Fernandez C, Lott MC, Chauffour A, Jarlier V, Farinotti R, Veziris N. 2010. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 54:4765-4771.
34. Van Deun A, Aung KJM, Bola V, Lebeke R, Hossain MA, de Rijk WB, Rigouts L, Gumusboga A, Torrea G, de Jong BC. 2013. Rifampin drug resistance tests for tuberculosis: Challenging the gold standard. J Clin Microbiol 51:2633-2640. http://dx.doi.org/10.1128/JCM.00553-13.